TN2009000277A1 - 3-substituted -[1,2,3]- benzotriazinone compound for enhancing glutamatergic synaptic reponses - Google Patents

3-substituted -[1,2,3]- benzotriazinone compound for enhancing glutamatergic synaptic reponses

Info

Publication number
TN2009000277A1
TN2009000277A1 TNP2009000277A TN2009000277A TN2009000277A1 TN 2009000277 A1 TN2009000277 A1 TN 2009000277A1 TN P2009000277 A TNP2009000277 A TN P2009000277A TN 2009000277 A TN2009000277 A TN 2009000277A TN 2009000277 A1 TN2009000277 A1 TN 2009000277A1
Authority
TN
Tunisia
Prior art keywords
treatment
compound
reponses
substituted
glutamatergic synaptic
Prior art date
Application number
TNP2009000277A
Other languages
English (en)
Inventor
Alexis Cordi
Gary Rogers
Rudolf Mueller
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of TN2009000277A1 publication Critical patent/TN2009000277A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
TNP2009000277A 2007-01-03 2009-06-30 3-substituted -[1,2,3]- benzotriazinone compound for enhancing glutamatergic synaptic reponses TN2009000277A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87850307P 2007-01-03 2007-01-03
US92143307P 2007-04-02 2007-04-02
PCT/US2007/026416 WO2008085506A1 (fr) 2007-01-03 2007-12-28 Composé de [1,2,3]-benzotriazinone 3-substituée destiné à améliorer les réponses synaptiques glutamatergiques

Publications (1)

Publication Number Publication Date
TN2009000277A1 true TN2009000277A1 (en) 2010-10-18

Family

ID=39608956

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000277A TN2009000277A1 (en) 2007-01-03 2009-06-30 3-substituted -[1,2,3]- benzotriazinone compound for enhancing glutamatergic synaptic reponses

Country Status (38)

Country Link
US (1) US8173644B2 (fr)
EP (1) EP2144506B1 (fr)
JP (1) JP5139446B2 (fr)
CN (1) CN101616592B (fr)
AP (1) AP2502A (fr)
AR (1) AR064740A1 (fr)
AT (1) ATE527269T1 (fr)
AU (1) AU2007342365B2 (fr)
BR (1) BRPI0720749A2 (fr)
CA (1) CA2674460C (fr)
CR (1) CR10906A (fr)
CU (1) CU23804B7 (fr)
CY (1) CY1112493T1 (fr)
DK (1) DK2144506T3 (fr)
EA (1) EA017437B1 (fr)
EC (1) ECSP099499A (fr)
ES (1) ES2374995T3 (fr)
GE (1) GEP20125438B (fr)
GT (1) GT200900189A (fr)
HK (1) HK1140105A1 (fr)
HN (1) HN2009001268A (fr)
HR (1) HRP20110970T1 (fr)
IL (1) IL199651A (fr)
MA (1) MA31160B1 (fr)
ME (1) ME00819B (fr)
MX (1) MX2009007242A (fr)
MY (1) MY154877A (fr)
NI (1) NI200900131A (fr)
NZ (1) NZ578293A (fr)
PL (1) PL2144506T3 (fr)
PT (1) PT2144506E (fr)
RS (1) RS52108B (fr)
SG (1) SG163545A1 (fr)
SI (1) SI2144506T1 (fr)
SV (1) SV2009003322A (fr)
TN (1) TN2009000277A1 (fr)
WO (1) WO2008085506A1 (fr)
ZA (1) ZA200904826B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007342364A1 (en) * 2007-01-03 2008-07-17 Cortex Pharmaceuticals, Inc. 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses
US8013003B2 (en) 2007-05-17 2011-09-06 Cortex Pharmaceuticals, Inc. Di-substituted amides for enhancing glutamatergic synaptic responses
SG163526A1 (en) 2007-08-10 2010-08-30 Cortex Pharma Inc Bicyclic amides for enhancing glutamatergic synaptic responses
US8119632B2 (en) 2007-08-10 2012-02-21 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
US20110257186A1 (en) * 2010-04-15 2011-10-20 Staubli Ursula V Compositions and methods for treating visual disorders
EP2784065B1 (fr) 2011-11-22 2016-10-05 Beijing Medisan Technology Co. Ltd. Inhibiteur de recaptage de glycine et son utilisation
FR3019464B1 (fr) * 2014-04-07 2016-05-06 Servier Lab Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent
FR3034019B1 (fr) * 2015-03-26 2017-03-17 Servier Lab Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un antidepresseur et les compositions pharmaceutiques qui la contiennent
AU2016284654B9 (en) 2015-06-26 2020-05-21 Takeda Pharmaceutical Company Limited 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor
CN106226509B (zh) * 2016-08-12 2019-09-06 中国人民解放军第四军医大学 一种在小鼠前扣带回皮层诱发dse现象的方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3723436A (en) 1971-02-25 1973-03-27 Sun Oil Co Process for aromatic lactams
DK623586A (da) * 1985-12-27 1987-06-28 Eisai Co Ltd Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
FR2597103B1 (fr) 1986-04-15 1988-12-16 Provesan Sa Procede de preparation de derives d'oxazinobenzothiazine 6,6-dioxyde
ATE215079T1 (de) 1992-07-24 2002-04-15 Univ California Arzneimittel, die den durch ampa rezeptoren vermittelten synaptischen respons erhöhen
US5962477A (en) * 1994-04-12 1999-10-05 Adolor Corporation Screening methods for cytokine inhibitors
DE59504622D1 (de) * 1994-10-31 1999-02-04 Merck Patent Gmbh Benzylpiperidinderivate mit hoher Affinität zu Bindungsstellen von Aminosäure-Rezeptoren
US5650409A (en) 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US5736543A (en) 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response
US6030968A (en) 1996-09-17 2000-02-29 The Regents Of The University Of California Positive AMPA receptor modulation to enhance brain neurotrophic factor expression
US6110935A (en) * 1997-02-13 2000-08-29 The Regents Of The University Of California Benzofurazan compounds for enhancing glutamatergic synaptic responses
US5985871A (en) * 1997-12-24 1999-11-16 Cortex Pharmaceuticals, Inc. Benzoxazine compounds for enhancing synaptic response
HUP0101280A3 (en) 1998-02-18 2003-02-28 Neurosearch As Positive ampa receptor modulator compounds and their use
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
US6303542B1 (en) * 2000-08-18 2001-10-16 Rohm And Haas Company Herbicidal 3-substituted-phenyl-1,2,3-benzotriazin-4-ones
EA011034B1 (ru) * 2001-11-26 2008-12-30 Кортекс Фармасеутикалс, Инк. Соединения карбонилбензоксазина для усиления глутаматергических синаптических ответов
JP2003238555A (ja) * 2002-02-20 2003-08-27 Sumitomo Pharmaceut Co Ltd 細胞死抑制剤
AUPS255202A0 (en) * 2002-05-27 2002-06-13 Monash University Agents and methods for the treatment of disorders associated with motor neuron degeneration
KR20050094840A (ko) * 2003-01-13 2005-09-28 코텍스 파마슈티칼스, 인크. 수면 부족 및 스트레스로 인한 인식 저하의 치료방법
GB0317482D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
AU2007342364A1 (en) 2007-01-03 2008-07-17 Cortex Pharmaceuticals, Inc. 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses
US8013003B2 (en) 2007-05-17 2011-09-06 Cortex Pharmaceuticals, Inc. Di-substituted amides for enhancing glutamatergic synaptic responses
SG163526A1 (en) 2007-08-10 2010-08-30 Cortex Pharma Inc Bicyclic amides for enhancing glutamatergic synaptic responses
WO2009038752A2 (fr) * 2007-09-20 2009-03-26 Cortex Pharmaceuticals, Inc. 1,2,3-triazine-4-ones 3-substituées et 1,3-pyrimidinones 3-substituées pour améliorer les réponses synaptiques glutamatergiques

Also Published As

Publication number Publication date
HRP20110970T1 (hr) 2012-01-31
NZ578293A (en) 2012-01-12
NI200900131A (es) 2010-03-11
MY154877A (en) 2015-08-14
AU2007342365B2 (en) 2012-11-15
CU23804B7 (es) 2012-03-15
MA31160B1 (fr) 2010-02-01
MX2009007242A (es) 2009-09-02
GT200900189A (es) 2011-08-02
ES2374995T3 (es) 2012-02-23
IL199651A (en) 2015-08-31
EP2144506A1 (fr) 2010-01-20
EP2144506A4 (fr) 2010-05-05
PL2144506T3 (pl) 2012-04-30
IL199651A0 (en) 2010-04-15
RS52108B (en) 2012-08-31
US20100137295A1 (en) 2010-06-03
JP2010514838A (ja) 2010-05-06
CA2674460C (fr) 2014-07-15
HN2009001268A (es) 2011-12-27
CR10906A (es) 2009-10-23
ZA200904826B (en) 2010-09-29
HK1140105A1 (en) 2010-10-08
US8173644B2 (en) 2012-05-08
DK2144506T3 (da) 2012-03-05
AP2502A (en) 2012-10-23
CN101616592A (zh) 2009-12-30
CN101616592B (zh) 2013-06-05
CA2674460A1 (fr) 2008-07-17
BRPI0720749A2 (pt) 2014-01-14
ECSP099499A (es) 2009-10-30
ME00819B (fr) 2012-03-20
EA017437B1 (ru) 2012-12-28
GEP20125438B (en) 2012-03-26
SV2009003322A (es) 2010-02-05
AU2007342365A1 (en) 2008-07-17
ATE527269T1 (de) 2011-10-15
AR064740A1 (es) 2009-04-22
SI2144506T1 (sl) 2012-01-31
WO2008085506A1 (fr) 2008-07-17
EP2144506B1 (fr) 2011-10-05
CY1112493T1 (el) 2015-12-09
CU20090117A7 (es) 2011-10-05
AP2009004931A0 (en) 2009-08-31
SG163545A1 (en) 2010-08-30
EA200900925A1 (ru) 2009-12-30
PT2144506E (pt) 2011-12-21
JP5139446B2 (ja) 2013-02-06

Similar Documents

Publication Publication Date Title
TN2009000277A1 (en) 3-substituted -[1,2,3]- benzotriazinone compound for enhancing glutamatergic synaptic reponses
TN2009000278A1 (en) 3-substituted-[1,2,3] benzotriazinone compounds for enhancing glutamatergic synaptic responses
MX2011002705A (es) Compuestos con anillos espiro-triciclicos como moduladores de beta-secretasas y metodos de uso.
EA201390971A1 (ru) ИМИДАЗО[5,1-f][1,2,4]ТРИАЗИНЫ ДЛЯ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ РАССТРОЙСТВ
WO2008050341A3 (fr) Agents psychotropes innovants présentant une activité du glutamate sur les récepteurs nmda
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
WO2009158467A3 (fr) Composés phényles disubstitués
MX2012010658A (es) Compuestos de anillo espiro tetraciclico como moduladores de beta-secretasa.
EP2977452A3 (fr) Procédés de traitement et de prévention de maladies et de troubles neurodégénératifs
WO2008148801A8 (fr) Nouvelles phénylpyrrolidines disubstituées en tant que modulateurs de la neurotransmission catécholaminergique corticale
NO20082923L (no) Anvendelse av en CB1 antagonist for behandling av bivirkninger og negative symptomer pa schizofreni
WO2012040727A3 (fr) Procédés de diagnostic et de traitement de maladies ou de troubles neurodégénératifs
GB2462235A (en) NMDA and MC receptor antagonists exhibiting neuroprotective and memory enhancing activities
JP2009537568A5 (fr)
WO2003045315A3 (fr) Composes carbonylbenzoxaziniques ameliorant les reponses synaptiques glutamatergiques
WO2007034326A3 (fr) Composes imidazoles pour le traitement de troubles neurologiques
UA93306C2 (ru) Соединение 3-замещенного-[1,2,3]-бензотриазинона для улучшения глутаматергических синаптических реакций
IL196615A0 (en) N-phenyl-prenylamine derivatives for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
ZA200900738B (en) Phenyi-prenyl-ether derivatives for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
WO2011123842A9 (fr) Méthodes de traitement de la maladie de parkinson et autres troubles des neurones dopaminergiques du cerveau
WO2011015646A3 (fr) Dérivés de furane-imidazolone pour le traitement de maladies ou troubles cognitifs, neurodégénératifs ou neuronaux
MX2011008060A (es) Derivados de amida biciclica para mejorar las respuestas sinapticas glutamatergicas.
TN2011000105A1 (en) Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use